The Impact of Insulin Glargine on Blood Glucose Control during On-Pump Beating Coronary Artery Bypass Surgery in Diabetic Patients: A Single-Blind Randomized Controlled Trial
-
Raheleh Ganjali
,
Mahdi Kahrom
,
Fatemeh Bijari
,
Masoomeh Tabari
,
Ali Golchoobi Firoozjah
,
Shima Sheybani
Abstract
Background: Diabetes mellitus in subjects of coronary artery bypass grafting (CABG) surgery is associated with increased morbidity and mortality. Therefore, in recent years, glycemic monitoring and control have been the focus of clinical research. This study aimed to determine the impact of insulin glargine on the management of blood glucose during the perioperative period of on-pump coronary artery bypass graft in diabetic patients.
Methods: In a randomized clinical trial, 80 patients with type 2 diabetes, candidates for elective CABG with a cardiopulmonary pump, were randomly separated into two groups. The intervention group received 0.2 units/kg of insulin glargine 2 hours before induction of anesthesia plus usual care. The control group received usual care. Usual care included injection of regular insulin before, during, and after surgery in accordance with a changed Van den Berghe code. Blood glucose (BG) level, ICU and hospital length of stay (LOS), creatinine, white blood cell count (WBC), and postoperative complications, including infection and dehiscence, were evaluated between two groups.
Results: The BG of patients upon entrance (p=0.04), 16 (p=0.01), 20 (p=0.01), and 24 (p=0.01) hours after admission to the ICU was significantly lower in the intervention than in the control group. There was a significant difference in the average BG levels at different times (p<0.001), so the highest and lowest BG levels were observed 4 and 20 hours after ICU administration in the intervention group and 4 hours and immediately after ICU admission in the control group. Average creatinine (p=0.01), regular insulin used until the end of the first day after surgery (p=0.01), ICU length of stay (LOS) (p=0.009), and hospital LOS (p=0.001) were significantly lower in the intervention group than the controls.
Conclusion: Insulin glargine plus regular insulin is able to maintain BG at a controlled level up to 24 hours after surgery. It also showed significant control over postoperative complications. This study revealed the therapeutic effectiveness of both insulin glargine and regular insulin in achieving adequate BG control for type 2 diabetes patients during the critical postoperative period of on-pump CABG.
[2] Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ. Screening for coronary artery disease in patients with diabetes. Diabetes care. 2007;30(10):2729-36.
[3] Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes care. 2004;27(5):1047-53.
[4] Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep. 2019;21(4):1-8.
[5] Ouattara A, Lecomte P, Le Manach Y, Landi M, Jacqueminet S, Platonov I, et al. Poor intraoperative blood glucose control is associated with a worsened hospital outcome after cardiac surgery in diabetic patients. Anesthesiology. 2005;103(4):687-94.
[6] Zhang X, Wu Z, Peng X, Wu A, Yue Y, Martin J, et al. Prognosis of Diabetic Patients Undergoing Coronary Artery Bypass Surgery Compared With Nondiabetics: A Systematic Review and Meta–analysis. Journal Cardiothorac Vasc Anesth. 2011;25(2):288-98.
[7] Shroyer AL, Grover FL, Hattler B, Collins JF, McDonald GO, Kozora E, et al. On-pump versus off-pump coronary-artery bypass surgery. N Engl J Med. 2009;361(19):1827-37.
[8] Lamy A, Devereaux P, Prabhakaran D, Taggart DP, Hu S, Paolasso E, et al. Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med. 2012;366(16):1489-97.
[9] Lamy A, Devereaux P, Prabhakaran D, Taggart DP, Hu S, Straka Z, et al. Five-year outcomes after off-pump or on-pump coronary-artery bypass grafting. N Engl J Med. 2016;375(24):2359-68.
[10] Huang K-C, Wu I-H, Chou N-K, Yang Y-Y, Lin L-C, Yu H-Y, et al. Late outcomes of off-pump versus on-pump coronary bypass in patients with diabetes: a nationwide study from Taiwan. J Thorac Cardiovasc Surg. 2019;157(3):960-9. e2.
[11] Godoy LC, Ko DT, Rao V, Farkouh ME. The role of coronary artery bypass surgery versus percutaneous intervention in patients with diabetes and coronary artery disease. Prog Cardiovasc Dis. 2019;62(4):358-63.
[12] Raza S, Sabik JF 3rd, Ainkaran P, Blackstone EH. Coronary artery bypass grafting in diabetics: A growing health care cost crisis. J Thorac Cardiovasc Surg. 2015;150(2):304-2.e2.
[13] Santos KAQ, Berto B, Sousa AG, Costa FAAd. Prognosis and complications of diabetic patients undergoing isolated coronary artery bypass surgery. Braz J CardiovascSurg. 2016; 31:07-14.
[14] Kogan A, Ram E, Levin S, Fisman EZ, Tenenbaum A, Raanani E, et al. Impact of type 2 diabetes mellitus on short-and long-term mortality after coronary artery bypass surgery. Cardiovasc Diabetol. 2018;17(1):1-8.
[15] Jones KW, Cain AS, Mitchell JH, Millar RC, Rimmasch HL, French TK, et al. Hyperglycemia predicts mortality after CABG: postoperative hyperglycemia predicts dramatic increases in mortality after coronary artery bypass graft surgery. J Diabetes Complicat. 2008;22(6):365-70.
[16] Szabó Z, Håkanson E, Svedjeholm R. Early postoperative outcome and medium-term survival in 540 diabetic and 2239 nondiabetic patients undergoing coronary artery bypass grafting. Ann Thorac Surg. 2002;74(3):712-9.
[17] Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation. 2004;109(12):1497-502.
[18] Robich MP, Iribarne A, Leavitt BJ, Malenka DJ, Quinn RD, Olmstead EM, et al. Intensity of glycemic control affects long-term survival after coronary artery bypass graft surgery. Ann Thorac Surg. 2019;107(2):477-84.
[19] Strahan S, Harvey RM, Campbell-Lloyd A, Beller E, Mundy J, Shah P. Diabetic control and coronary artery bypass: effect on short-term outcomes. Asian Cardiovasc Thorac Ann. 2013;21(3):281-7.
[20] Lazar HL, McDonnell M, Chipkin SR, Furnary AP, Engelman RM, Sadhu AR, et al. The Society of Thoracic Surgeons practice guideline series: blood glucose management during adult cardiac surgery. Ann Thorac Surg. 2009;87(2):663-9.
[21] Hirsch IB. Insulin analogues. N Engl J Med. 2005;352(2):174-83.
[22] Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23(5):644-9.
[23] Gandhi H, Sarvaia A, Malhotra A, Acharya H, Shah K, Rajavat J. Effects of glargine insulin on glycemic control in patients with diabetes mellitus type II undergoing off-pump coronary artery bypass graft. Ann Card Anaesth. 2018;21(2):167.
[24] Yeldandi RR, Lurie A, Baldwin D. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery. Diabetes Technol Ther. 2006;8(6):609-16.
[25] Nader ND, Hamishehkar H, Naghizadeh A, Shadvar K, Iranpour A, Sanaie S, et al. Effect of adding insulin glargine on glycemic control in critically Ill patients admitted to intensive care units: a prospective randomized controlled study. Diabetes, Metab Syndr.2020;13:671.
[26] Latham R, Lancaster AD, Covington JF, Pirolo JS, Thomas CS. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Control Hosp Epidemiol. 2001;22(10):607-12.
[27] Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg. 1999;67(2):352-60.
[28] Seyed Khalil F, Seyed Mohammad M, Seyed Jalil M, Seyed Hossain M, Habibbolla H, Seyed Ali B, et al. Comparing effects of continuous insulin infusion with or without subcutaneous glargine insulin on glycemic control in diabetic patients undergoing coronary artery bypass graft [CABG]. 2010.
| Files | ||
| Issue | Article in Press |
|
| Section | Research Article(s) | |
| Keywords | ||
| Coronary Artery Bypass Grafting Cardiopulmonary Pump Type 2 diabetes Blood Glucose level Regular insulin | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
